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Finding the Missing Pieces: Comprehensive Cerebellar Assessments with Cytarabine Administration 
CASE STUDY: 
Stan (name changed for confidentiality) was a 60 year old male admitted to the hospital with relapsed AML in the 
summer of 2015 after two years of remission. Stan was first diagnosed three years earlier and subsequently underwent 
chemotherapy and stem cell transplant with no known neurotoxicity. In 2015, re-induction chemotherapy 7 + 3 with 
Idarubicin and Cytarabine was completed in the hospital. Prior to treatment, Stan was walking independently with no 
functional deficits. Current standard of practice at the St. Cloud Hospital for cerebellar monitoring included having the 
patient sign his/her name daily. 
 ▪ Day 1 Post Chemo at 0800: Patient reported increased bilateral lower extremity weakness with walking. IV fluids 
  were initiated. No deficits noted in signing of the name. 
 ▪ Day 1 Post Chemo at 2300: Patient is now unable to void, requiring ongoing straight catheterizations. Stan reports 
  inability to walk, has significant decreased sensations in bilateral lower extremities. Still able to sign his name  
  without deficits noted. 
 ▪ Day 2 Post Chemo at 0800: Neurology consulted. Stan reports weakness has reached his bilateral upper  
  extremities. MRI of lumbar, thoracic, cervical and head all negative. Findings all suggest acute paraplegia and  
  painful peripheral neuropathy as a result of acute cytarabine neurotoxicity.  
 ▪ Within several weeks of ongoing therapy, patient had regained all bowel/bladder function and most function and  
  strength in bilateral upper and lower extremities. 
 
DISCUSSION: 
▪ There were several unknown variables to explain why Stan experienced probable neurotoxicity with non-high dose 
 therapy. No data was available regarding therapies received prior to transplant. There is a possibility the patient had 
 exceeded the recommended lifetime dose limit and/or had a previous neurotoxic reaction in the past, making him more 
 susceptible.  
▪ The case was discussed with Kathleen Rieke, MD of Neurology. Dr. Rieke recommends any patients receiving 
 Cytarabine in ANY strength be assessed for neurotoxicity, including assessment of motor strength and function of 
 all four extremities every shift.  
WHAT IS CYTARABINE?  
Cytarabine (Ara-C) is an anti-metabolite chemotherapy agent used to treat  
acute leukemia and/or refractory non-hodgkin’s lymphoma . The drug  
is cell-cycle specific and inhibits DNA synthesis thus halting cell division.  
The dose-limiting toxicity of this drug is NEUROTOXICITY, especially 
when given in high-dose concentration  (Szoch & Kaiser, 2015). This is 
caused by a widespread loss of Purkinje cells in the cerebellum (Lee & 
Wen, 2015).  With high-dose cytarabine administration, there is a high 
concentration of drug that crosses the blood-brain barrier in the cerebral 
spinal fluid with 50% of the chemotherapy still in the plasma 
concentration (O’Leary, 2004).  
 
WHEN IT BECOMES NEUROTOXIC 
▪ Patient’s receiving high-dose cytarabine have a 7-28% incidence of 
 developing neurotoxicity; high doses include ≥ 1-3g/m² (Lee & Wen, 
   2015). 
▪ 10-25% of patient’s develop neurotoxicity when the cumulative dose 
 exceeds 30 grams in a lifetime (Lee & Wen, 2015). 
▪ There is a 60% incidence of cerebellar toxicity reoccurrence for 
 patient’s who showed previous toxicity (O’Leary, 2004). 
▪ Other risk factors include decreased hepatic and/or renal dysfunction 
 and/or age >60 years old (Szoch & Kaiser, 2015). 
▪ Symptoms usually develop 2-8 days after initial dose and may persist 3-
 10 days after discontinuation of therapy (O’Leary, 2004).  
▪ For those >50 years old, symptoms may persist for more than 30 days 
 even if therapy is stopped (O’Leary, 2004). 
▪ Up to 30% of patients may not regain normal cerebellar function 
 (O’Leary, 2004). 
▪ Symptoms include gait and balance disturbances, alterations in fine 
 motor skills, memory loss, peripheral neuropathy and/or seizures (Lee 
 & Wen, 2015).  
NURSING 
CONSIDERATIONS 
A study conducted at the  
University of Maryland  
Greenebaum Cancer Center found 
that one in four nurses felt there were 
widespread inconsistencies with 
cerebellar assessments. One of every 
two nurses felt the current assessment 
was incomplete and the patient may 
be suffering as a result. 
 (Szoch & Kaiser, 2015)  
There has to be a better way! 
 
COMPONENTS OF A COMPREHENSIVE ASSESSMENT 
 
▪ Nurses need to have the means to accurately and consistently assess and document neurological changes noted with Cytarabine administration. The  
 assessment tool must be comprehensive, covering several areas of cerebellum function. Assessments should be completed every shift and/or prior to 
 each dose of cytarabine (Brown & Hall, 2010) (O’Leary, 2004). 
 
▪ The initial assessment and first dose of High-Dose Cytarabine should be completed during the day time hours to promote patient satisfaction and ensure 
 accuracy of assessment (Szoch & Kaiser, 2015). 
 
▪ The assessment should be relatively short in time (approximately 5-10 minutes or less); especially with the increased demands placed on hospital-based 
 nursing care. Tool should be easy to understand for nurses at all skill levels and integrated into current charting practice (Brown, 2010).  
 
▪ If the patient fails any aspect of the assessment, the upcoming dose should be held and the oncologist notified immediately. If the patient is to receive 
 medications that may alter gross motor skills, such as narcotics, a cerebellar assessment should be completed prior to administration to ensure accuracy 
 of the assessment (O’Leary, 2004).  
▪ Crucial components of cerebral and cerebellar functional assessments include: (Brown, 2010) (Szoch & Kaiser, 2015)  
 Gait and balance: Watch for signs of arrhythmia or asymmetry. This is best completed by patient walking heel to toe in straight line.
 Handwriting: Most often monitored by signing his/her name; preference to utilize a skill that usually doesn’t change over time.  
 Speech Pattern: Have patient state name, date, time, and situation. 
 Body Tremors: Monitor for tremors while standing or walking. 
 Nystagmus: When present, this will cause involuntary rapid eye movement when attempting to focus on an object. 
 Point – to – Point Testing: Patient’s finger directly makes contact with observer’s finger and his/her own nose several times as observer 
  moves throughout patient’s vision field.  
 Rapid alternating hand movements: Patient will pat hands on thighs in rhythmic motion as fast as possible without losing  
  coordination. 
 Romberg Test: Measures three sensory systems in cerebellum to maintain stability, including vision, proprioception and vestibular sense. 
   To complete successfully, patient will stand with feet together and eyes closed for 5-10 seconds. 
   (Brown, 2010) (Szoch & Kaiser, 2015)  
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